INTELLIGENT BIO SOLUTIONS INC (INBS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.23-3.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
INBS aims to grow revenue 36% year-over-year. Revenue rose from $2.01M to $3.07M recently. The company focuses on fast, precise drug abuse tests. This growth shows early progress in a tough market.
INBS is still losing money and faces a 46% stock drop. Revenue is small and earnings are negative. The company missed past earnings and risks delisting. These problems could stop the turnaround.
The market expects 78% revenue growth, which is very high. Our fair value is about $12, close to current price. We see risk in meeting these high growth hopes.
Breaks if: Gross margin falls below 45% next year
Breaks if: EPS loss worsens beyond -$6.00 in FY27
Breaks if: YoY revenue growth falls below 20% next year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. The company is currently loss-making but is focused on increasing revenue and improving margins, which are critical for its long-term thesis.
The market appears to have priced in a low level of fragility, suggesting that there are no immediate concerns about the company's stability. However, the valuation is considered cheap compared to peers, indicating that expectations may be lower than for similar companies.
Management is on track with key priorities, including revenue growth and margin improvement, but recent financial performance has been weak. There is a high risk of missing earnings expectations in the near term, which could impact sentiment.
The thesis hinges on the company's ability to maintain momentum in revenue growth and margin improvement while navigating potential earnings misses. Additionally, the performance of larger healthcare peers could influence market sentiment and sector momentum.
The most important moves since the prior daily snapshot.
Valuation fell by 30.1 points (from 54.9 to 24.8).
Signal changed from 'mild_favorable' to 'mixed'.
Composite insight fell by 10.7 points (from 12.4 to 1.7).
Yes, our read has strengthened. The company reported a 38% year-over-year revenue growth. This growth aligns with management's objectives and supports a more favorable outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, INBS is in a watch state with mixed signals, and its future performance will depend on execution and external market factors. Not investment advice.